Gene therapy with Adeno-associated viruses. © NIH

As first gene therapy ever, AMT-130 has been granted FDA Orphan Drug status in Huntington’s Disease.

© Sartorius

Microsart ® @media Advanced System for Touch-free Membrane Transfer.

Robotic cell culture system CellPROi. © Shibuya Corp.

Promethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform.

Immatics headquarters in Tuebingen. © Immatics Biotechnologies

Cancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well as Wellington Partners and new investor Amgen.

Kathryn J. Gregory

Late-stage pharmaceuticals financing and co-development specialist Avillion LLP has named Kathryn J. Gregory Chief Business Officer.

Mode of action of NuCana's ProTides compared to those of gemcitabine (above). © NuCana plc

Scotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair.

Up to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported a way to track changes with whole-tissue biospy phenotyping.

Sébastien Stoitzner, CEO. © Gensearch

The European Biotech market is extremely dynamic, acknowledged as being number two in the world of market rankings. This is a cause for celebration!

Mode of action of caplacizumab. © Ablynx

Belgian nanobody developer Ablynx NV‘s nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP),  paving the way to market authorisation in Europe and the US.

© Sartorius

Active sampling of airborne viruses, bacteria, yeasts and fungi.